Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 23, 2022 - Issue 6
Submit an article Journal homepage
56,383
Views
17
CrossRef citations to date
0
Altmetric
Original Investigations

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce

Jerome Sarrisa NICM Health Research Institute, Western Sydney University, Westmead, Australia;b The Professorial Unit, The Melbourne Clinic; Department of Psychiatry, University of Melbourne, Melbourne, Australia;c Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, University of Melbourne, Melbourne, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9287-8854
ORCID Icon,
Arun Ravindrand University of Toronto and Centre for Addiction and Mental Health, Toronto, Canada
,
Lakshmi N. Yathame University of British Columbia, Vancouver, Canada
,
Wolfgang Marxf Deakin University, IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, AustraliaORCID Iconhttps://orcid.org/0000-0002-8556-8230
ORCID Icon,
Julia J. Rucklidgeg School of Psychology, Speech, and Hearing, University of Canterbury, Christchurch, New ZealandORCID Iconhttps://orcid.org/0000-0003-3793-7342
ORCID Icon,
Roger S. McIntyreh University of Toronto, Mood Disorders Psychopharmacology Unit, Toronto, CanadaORCID Iconhttps://orcid.org/0000-0003-4733-2523
ORCID Icon,
Shahin Akhondzadehi Psychiatry and Psychology Research Centre, Roozbeh Hospital, Tehran University of Medical Science, Tehran, Iran
,
Francesco Benedettij School of Medicine, Università Vita-Salute San Raffaele, Milan, Italy;k Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, ItalyORCID Iconhttps://orcid.org/0000-0003-4949-856X
ORCID Icon,
Constanza Caneol Departamento de Psiquiatría, Pontificia Universidad Católica de Chile, Santiago, ChileORCID Iconhttps://orcid.org/0000-0002-8477-3590
ORCID Icon,
Holger Cramerm Department of Internal and Integrative Medicine, Faculty of Medicine, University of Duisburg-Essen, Essen, GermanyORCID Iconhttps://orcid.org/0000-0002-3640-8046
ORCID Icon,
Lachlan Cribbb The Professorial Unit, The Melbourne Clinic; Department of Psychiatry, University of Melbourne, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0001-5276-5249
ORCID Icon,
Michael de Manincora NICM Health Research Institute, Western Sydney University, Westmead, AustraliaORCID Iconhttps://orcid.org/0000-0003-0612-4891
ORCID Icon,
Olivia Deanf Deakin University, IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia;n Mental Health Research Institute of Victoria, Parkville, AustraliaORCID Iconhttps://orcid.org/0000-0002-2776-3935
ORCID Icon,
Andrea Camaz Deslandeso Center for Alzheimer’s Disease and Related Disorders, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0001-5941-9111
ORCID Icon,
Marlene P. Freemanp Women’s Mental Health Program, Department of Psychiatry, Obstetrics and Gynaecology and Department of Nutritional Sciences, College of Medicine, University of Arizona, Tucson, United States
,
Bangalore Gangadharq Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, IndiaORCID Iconhttps://orcid.org/0000-0002-9887-6515
ORCID Icon,
Brian H. Harveyr Division of Pharmacology, Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, North West University, Potchefstroom, South AfricaORCID Iconhttps://orcid.org/0000-0002-9864-7894
ORCID Icon,
Siegfried Kaspers Department of Psychiatry and Psychotherapy, Center for Brain Research, Medical University of Vienna, Vienna, AustriaORCID Iconhttps://orcid.org/0000-0001-8278-191X
ORCID Icon,
James Lakea NICM Health Research Institute, Western Sydney University, Westmead, Australia;t Department of Psychiatry, University of Arizona, Tuscon, United States
,
Adrian Loprestiu College of Science, Health, Engineering and Education, Murdoch University, Murdoch, AustraliaORCID Iconhttps://orcid.org/0000-0002-6409-7839
ORCID Icon,
Lin Luv Institute of Mental Health and Peking University Sixth Hospital, Peking University and National Institute of Drug Dependence, Beijing, China
,
Najwa-Joelle Metria NICM Health Research Institute, Western Sydney University, Westmead, AustraliaORCID Iconhttps://orcid.org/0000-0002-5221-0566
ORCID Icon,
David Mischoulonw Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-7233-5860
ORCID Icon,
Chee H. Ngb The Professorial Unit, The Melbourne Clinic; Department of Psychiatry, University of Melbourne, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-3811-2732
ORCID Icon,
Daisuke Nishix Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-9349-3294
ORCID Icon,
Roja Rahimiy Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Science, Tehran, IranORCID Iconhttps://orcid.org/0000-0001-8637-4350
ORCID Icon,
Soraya Seedatz Department of Psychiatry, Stellenbosch University, Cape Town, South AfricaORCID Iconhttps://orcid.org/0000-0002-5118-786X
ORCID Icon,
Justin Sinclaira NICM Health Research Institute, Western Sydney University, Westmead, AustraliaORCID Iconhttps://orcid.org/0000-0001-9960-3191
ORCID Icon,
Kuan-Pin Suaa Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan;ab An-Nan Hospital, China Medical University, Tainan, TaiwanORCID Iconhttps://orcid.org/0000-0002-4501-2502
ORCID Icon,
Zhang-Jin Zhangac School of Chinese Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China;ad Department of Chinese Medicine, the University of Hong Kong – Shenzhen Hospital, Shenzhen, ChinaORCID Iconhttps://orcid.org/0000-0002-8416-3426
ORCID Icon &
Michael Berkc Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, University of Melbourne, Melbourne, Australia;f Deakin University, IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia;ae Orygen, National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Parkville, AustraliaORCID Iconhttps://orcid.org/0000-0002-5554-6946
ORCID Icon show all
Pages 424-455 | Received 09 Jun 2021, Accepted 29 Nov 2021, Published online: 21 Mar 2022

References

  • Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, Akhondzadeh S. 2011. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev. 42(3):367–375.
  • Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri M, Moin M, Khani M, Jamshidi AH, Baghalian K, Taghizadeh M. 2003. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 27(1):123–127.
  • Akhondzadeh S, Mohammadi M-R, Khademi M. 2004. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 4(1):1–6.
  • Alghamdi S, Alsulami N, Khoja S, Alsufiani H, Tayeb HO, Tarazi FI. 2020. Vitamin D supplementation ameliorates severity of major depressive disorder. J Mol Neurosci. 70(2):230–235.
  • Aman MG, Mitchell EA, Turbott SH. 1987. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol. 15(1):75–90.
  • Amr M, El-Mogy A, Shams T, Vieira K, Lakhan SE. 2013. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutr J. 12(1):31–31.
  • Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. 2009. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 29(4):378–382.
  • Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R. 2000. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of withania somnifera. Indian J Psychiatry. 42(3):295–301.
  • Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JN, Sorbero ME, Hempel S. 2016. A systematic review of St. John’s wort for major depressive disorder. Syst Rev. 5(1):148.
  • Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, et al. 2007. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 17(6):791–802.
  • Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. 1989. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry. 25(2):222–228.
  • Arnold LE, Disilvestro RA, Bozzolo D, Bozzolo H, Crowl L, Fernandez S, Ramadan Y, Thompson S, Mo X, Abdel-Rasoul M, et al. 2011. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol. 21(1):1–19.
  • Barić H, Đorđević V, Cerovečki I, Trkulja V. 2018. Complementary and alternative medicine treatments for generalized anxiety disorder: systematic review and meta-analysis of randomized controlled trials. Adv Ther. 35(3):261–288.
  • Bauer I, Green C, Colpo GD, Durkin K, Selvaraj S, Teixeira AL, Zunta-Soares GB, Soares JC. 2017. A double-blind randomized placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar disorder patient: preliminary findings. London (UK): Nature Publishing Group.
  • Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, Lewis H, Lloyd K, McCaddon A, Moat S, et al. 2014. Folate augmentation of treatment–evaluation for depression (FolATED): randomised trial and economic evaluation. Health Technol Assess. 18(48):vii–viii.
  • Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI. 2008. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry. 64(6):468–475.
  • Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, et al. 2012. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 10(1):91.
  • Bilici M, Yildirim F, Kandil S, Bekaroğlu M, Yildirmiş S, Değer O, Ulgen M, Yildiran A, Aksu H. 2004. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 28(1):181–190.
  • Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. 2013. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 52(3):231–240.
  • Borrelli F, Izzo AA. 2009. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. Aaps J. 11(4):710–727.
  • Braun L, Cohen M. 2015. Herbs and natural supplements: an evidence-based guide. Chatswood (Australia): Elsevier.
  • Çakici N, Van Beveren N, Judge-Hundal G, Koola M, Sommer I. 2019. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 49(14):2307–2319.
  • Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstetr Gynecol. 201(6):579.e571–579.e578.
  • Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. 2019. A randomized placebo-controlled trial of omega-3 and sertraline in depressed patients with or at risk for coronary heart disease. J Clin Psychiatry. 80(4):0–0.
  • Chang C-H, Tseng P-T, Chen N-Y, Lin P-C, Lin P-Y, Chang JP-C, Kuo F-Y, Lin J, Wu M-C, Su K-P. 2017. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids. 129:1–12.
  • Chang JP-C, Su K-P, Mondelli V, Pariante CM. 2018. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacol. 43(3):534–545.
  • Chang JP-C, Chang S-S, Yang H-T, Chen H-T, Chien Y-C, Yang B, Su H, Su K-P. 2020. Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder–results from a randomized controlled trial. Brain Behav Immun. 85:14–20.
  • Chavez ML, Jordan MA, Chavez PI. 2006. Evidence-based drug–herbal interactions. Life Sci. 78(18):2146–2157.
  • Chen X, Hong Y, Zheng P. 2015. Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Psychiatry Res. 228(1):121–127.
  • Cheng YC, Huang YC, Huang WL. 2020. The effect of vitamin D supplement on negative emotions: a systematic review and meta‐analysis. Depress Anxiety. 37(6):549–564.
  • Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. 2013. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 74(11):1076–1083.
  • Choudhary D, Bhattacharyya S, Joshi K. 2017. Body weight management in adults under chronic stress through treatment with Ashwagandha root extract: a double-blind, randomized, placebo-controlled trial. J Evid Based Complementary Altern Med. 22(1):96–106.
  • Cornu C, Mercier C, Ginhoux T, Masson S, Mouchet J, Nony P, Kassai B, Laudy V, Berquin P, Franc N, et al. 2018. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. Eur Child Adolesc Psychiatry. 27(3):377–384.
  • Correll CU, Carlson HE. 2006. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 45(7):771–791.
  • Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD. 2004. Herb-drug interactions: an evidence based approach. Curr Med Chem. 11(11):1513–1525.
  • Crippa A, Tesei A, Sangiorgio F, Salandi A, Trabattoni S, Grazioli S, Agostoni C, Molteni M, Nobile M. 2019. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Eur Child Adolesc Psychiatry. 28(4):571–583.
  • Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. 2007. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 61(5):343–348.
  • DellaPenna D. 1999. Nutritional genomics: manipulating plant micronutrients to improve human health. Science. 285(5426):375–379.
  • Donini LM, Scardella P, Piombo L, Neri B, Asprino R, Proietti AR, Carcaterra S, Cava E, Cataldi S, Cucinotta D, et al. 2013. Malnutrition in elderly: social and economic determinants. J Nutr Health Aging. 17(1):9–15.
  • Ellegaard PK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, Mohebbi M, Nielsen CT. 2019. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 245:1043–1051.
  • Farshbaf-Khalili A, Kamalifard M, Namadian M. 2018. Comparison of the effect of lavender and bitter orange on anxiety in postmenopausal women: a triple-blind, randomized, controlled clinical trial. Complement Ther Clin Pract. 31:132–138.
  • Fava M, Mischoulon D. 2009. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 70(Suppl 5):12–17.
  • Firth J, Teasdale SB, Allott K, Siskind D, Marx W, Cotter J, Veronese N, Schuch F, Smith L, Solmi M, et al. 2019. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta‐review of meta‐analyses of randomized controlled trials. World Psychiatry. 18(3):308–324.
  • Freedman R, Hunter SK, Hoffman MC. 2018. Prenatal primary prevention of mental illness by micronutrient supplements in pregnancy. Am J Psychiatry. 175(7):607–619.
  • Fristad MA, Vesco AT, Young AS, Healy KZ, Nader ES, Gardner W, Seidenfeld AM, Wolfson HL, Arnold LE. 2019. Pilot randomized controlled trial of omega-3 and individual–family psychoeducational psychotherapy for children and adolescents with depression. J Clin Child Adolesc Psychol. 48(sup1):S105–S118.
  • Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A. 2020. Assessment of Withania somnifera root extract efficacy in patients with generalized anxiety disorder: a randomized double-blind placebo-controlled trial. Curr Clin Pharmacol. 16(2):191–196.
  • Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, Petralia A, Signorelli MS, Aguglia E. 2020. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr. 60(15):2643–2653.
  • Gabbay V, Freed RD, Alonso CM, Senger S, Stadterman J, Davison BA, Klein RG. 2018. A double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression. J Clin Psychiatry. 79(4):17m11596.
  • Gadallah A-HA, Ebada MA, Gadallah A, Ahmed H, Rashad W, Eid KA, Bahbah E, Alkanj S. 2020. Efficacy and safety of N-acetyl-cysteine as add-on therapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis. J Obsessive-Compulsive Relat Disord. 25:100529.
  • Gan J, Galer P, Ma D, Chen C, Xiong T. 2019. The effect of vitamin D supplementation on attention-deficit/hyperactivity disorder: a systematic review and meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacol. 29(9):670–687.
  • Grandhi S, Donnelly LE, Rogers DF. 2007. Phytoceuticals: the new ‘physic garden’ for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med. 1(2):227–246.
  • Grant JE, Odlaug BL, Kim SW. 2009. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 66(7):756–763.
  • Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, et al. 2019. International society for nutritional psychiatry research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 88(5):263–273.
  • Harnett JE, McIntyre E, Steel A, Foley H, Sibbritt D, Adams J. 2019. Use of complementary medicine products: a nationally representative cross-sectional survey of 2019 Australian adults. BMJ Open. 9(7):e024198.
  • Harris PE, Cooper KL, Relton C, Thomas KJ. 2012. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract. 66(10):924–939.
  • Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Moller HJ, Kasper S, Chairs WGTF; WFSBP Guideline Task Force Chairs 2019. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry. 20(1):2–16.
  • Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. 2002. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 54(4):349–356.
  • Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia CE, Tortoriello J. 2007. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 73(8):713–717.
  • Herrera-Arellano A, Jimenez-Ferrer J, Zamilpa A, García-Alonso G, Herrera-Alvarez S, Tortoriello J. 2012. Therapeutic effectiveness of Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med. 78(14):1529–1535.
  • Hsu MC, Huang YS, Ouyang WC. 2020. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. Lipids Health Dis. 19(1):159.
  • Lyoo IK, Yoon S, Kim T-S, Hwang J, Kim JE, Won W, Bae S, Renshaw PF. 2012. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry. 169(9):937–945.
  • Jana T, Zuzana H, Anna S, Barbora K, Irina G, Iveta W, Katarína S, Iveta G, Ján Š, Zdeňka Ď. 2020. Omega-3 fatty-acids modulate symptoms of depressive disorder, serum levels of omega-3 fatty acids and omega-6/omega-3 ratio in children. A randomized, double-blind and controlled trial. Psychiatry Research. 287:112911.
  • Johnstone JM, Hughes A, Goldenberg JZ, Romijn AR, Rucklidge JJ. 2020. Multinutrients for the treatment of psychiatric symptoms in clinical samples: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 12(11):3394.
  • Kar S, Wong M, Rogozinska E, Thangaratinam S. 2016. Effects of omega-3 fatty acids in prevention of early preterm delivery: a systematic review and meta-analysis of randomized studies. Eur J Obstet Gynecol Reprod Biol. 198:40–46.
  • Kasper S, Caraci F, Forti B, Drago F, Aguglia E. 2010. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 20(11):747–765.
  • Kasper S, Anghelescu I, Dienel A. 2015. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 25(11):1960–1967.
  • Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A. 2014. Lavender oil preparation Silexan is effective in generalized anxiety disorder–a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharm. 17(06):859–869.
  • Klimova B, Novotny M, Valis M. 2020. The impact of nutrition and intestinal microbiome on elderly depression—a systematic review. Nutrients. 12(3):710.
  • Knippenberg S, Damoiseaux J, Bol Y, Hupperts R, Taylor BV, Ponsonby AL, Dwyer T, Simpson S, van der Mei IA. 2014. Higher levels of reported sun exposure, and not vitamin D status, are associated with less depressive symptoms and fatigue in multiple sclerosis. Acta Neurol Scand. 129(2):123–131.
  • Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, Hess S, Sagy R, Kimhi-Nesher S, Kalter E, et al. 2017. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine. 26:138–145.
  • Kuchta K, de Nicola P, Schmidt M. 2018. Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients. Tradit Kampo Med. 5(1):3–10.
  • Lassi ZS, Salam RA, Haider BA, Bhutta ZA. 2013. Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes. Cochrane Database Syst Rev. (3):CD006896.
  • Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM. 2000. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatry Neurosci. 25(4):337–346.
  • Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. 2020. N-acetylcysteine for pediatric obsessive-compulsive disorder: a small pilot study. J Child Adolesc Psychopharmacol. 30(1):32–37.
  • Lin P-Y, Chang C-H, Chong MF-F, Chen H, Su K-P. 2017. Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis. Biol Psychiatry. 82(8):560–569.
  • Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. 2016. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial. Phytomedicine. 23(14):1735–1742.
  • Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD. 2015. Rhodiola rosea versus sertraline for major depressive disorder: a randomized placebo-controlled trial. Phytomedicine. 22(3):394–399.
  • Marx W, Lane M, Hockey M, Aslam H, Berk M, Walder K, Borsini A, Firth J, Pariante CM, Berding K, et al. 2021. Diet and depression: exploring the biological mechanisms of action. Mol Psychiatry. 26(1):134–117.
  • Marx W, Lane M, Rocks T, Ruusunen A, Loughman A, Lopresti A, Marshall S, Berk M, Jacka F, Dean OM. 2019. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutr Rev. 1–15.
  • Mehdi SM, Atlas SE, Qadir S, Musselman D, Goldberg S, Woolger JM, Corredor R, Abbas MH, Arosemena L, Caccamo S, et al. 2017. Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. Psychiatry Clin Neurosci. 71(3):204–211.
  • Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. 2015. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 76(01):54–61.
  • Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, et al. 2014. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 75(04):370–376.
  • Mocking RJ, Steijn K, Roos C, Assies J, Bergink V, Ruhé HG, Schene AH. 2020. Omega-3 fatty acid supplementation for perinatal depression: a meta-analysis. J Clin Psychiatry. 81(5):0–0.
  • Mocking R, Harmsen I, Assies J, Koeter M, Ruhé H, Schene A. 2016. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 6(3):e756–e756.
  • Mohammadzadeh S, Baghi N, Yousefi F, Yousefzamani B. 2019. Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean J Pediatr. 62(9):360–366.
  • Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA Group 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7):e1000097.
  • Mukai T, Kishi T, Matsuda Y, Iwata N. 2014. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 29(1):55–63.
  • Murphy BL, Stoll AL, Harris PQ, Ravichandran C, Babb SM, Carlezon WA, Jr, Cohen BM. 2012. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 32(5):699–703.
  • Nagpal R, Mainali R, Ahmadi S, Wang S, Singh R, Kavanagh K, Kitzman DW, Kushugulova A, Marotta F, Yadav H. 2018. Gut microbiome and aging: physiological and mechanistic insights. Nutr Healthy Aging. 4(4):267–285.
  • Nemets B, Levine J. 2013. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. Int Clin Psychopharmacol. 28(3):127–133.
  • Nikfarjam M, Parvin N, Assarzadegan N, Asghari S. 2013. The effects of Lavandula angustifolia mill infusion on depression in patients using citalopram: a comparison study. Iran Red Crescent Med J. 15(8):734–739.
  • Nikfarjam M, Rakhshan R, Ghaderi H. 2017. Comparison of effect of Lavandula officinalis and venlafaxine in treating depression: a double blind clinical trial. J Clin Diagn Res. 11(7):KC01–KC04.
  • Noorazar SG, Malek A, Aghaei SM, Yasamineh N, Kalejahi P. 2020. The efficacy of zinc augmentation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: a randomized controlled trial. Asian J Psychiatr. 48:101868.
  • Pancheri P, Scapicchio P, Chiaie RD. 2002. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 5(4):287–294.
  • Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. 2010. S-Adenosyl Methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 167(8):942–948.
  • Parletta N, Milte CM, Meyer BJ. 2013. Nutritional modulation of cognitive function and mental health. J Nutr Biochem. 24(5):725–743.
  • Popper C, Kaplan B, Rucklidge J. 2017. Single and broad-spectrum micronutrient treatments in psychiatry practice. Arlington, VA: American Psychiatric Association Publishing.
  • Posadzki P, Watson L, Ernst E. 2013. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 69(3):295–307.
  • Qiao Y, Liu CP, Han HQ, Liu FJ, Shao Y, Xie B. 2020. No impact of omega-3 fatty acid supplementation on symptoms or hostility among patients with schizophrenia. Front Psychiatry. 11:312.
  • Ramsay NA, Kenny MW, Davies G, Patel JP. 2005. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol. 130(5):777–780.
  • Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D. 2016. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 21(1):71–79.
  • Ratsika A, Codagnone MC, O’Mahony S, Stanton C, Cryan JF. 2021. Priming for life: early life nutrition and the microbiota-gut-brain axis. Nutrients. 13(2):423.
  • Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, Kennedy SH, Lam RW, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. Complementary and alternative medicine treatments. Can J Psychiatry. 61(9):576–587.
  • Ravindran AV, Lam RW, Filteau MJ, Lesperance F, Kennedy SH, Parikh SV, Patten SB, Canadian Network for Mood and Anxiety Treatments (CANMAT). 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord. 117 Suppl 1(Suppl 1):S54–S64.
  • Reddy VS, Palika R, Ismail A, Pullakhandam R, Reddy GB. 2018. Nutrigenomics: opportunities & challenges for public health nutrition. Indian J Med Res. 148(5):632–641.
  • Roberts E, Carter B, Young AH. 2018. Caveat emptor: folate in unipolar depressive illness, a systematic review and meta-analysis. J Psychopharmacol. 32(4):377–384.
  • Rodriguez C, Garcia T, Areces D, Fernandez E, Garcia-Noriega M, Domingo JC. 2019. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatr Dis Treat. 15:1193–1209.
  • Rucklidge JJ, Frampton CM, Gorman B, Boggis A. 2014. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. Br J Psychiatry. 204:306–315.
  • Rucklidge JJ, Eggleston MJF, Johnstone JM, Darling K, Frampton CM. 2018. Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-controlled trial. J Child Psychol Psychiatry. 59(3):232–246.
  • Ryszewska-Pokraśniewicz B, Mach A, Skalski M, Januszko P, Wawrzyniak ZM, Poleszak E, Nowak G, Pilc A, Radziwoń-Zaleska M. 2018. Effects of magnesium supplementation on unipolar depression: a placebo-controlled study and review of the importance of dosing and magnesium status in the therapeutic response. Nutrients. 10(8):1014.
  • Sahraian A, Ghanizadeh A, Kazemeini F. 2015. Vitamin C as an adjuvant for treating major depressive disorder and suicidal behavior, a randomized placebo-controlled clinical trial. Trials. 16:94–94.
  • Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N. 2018. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology (Berl). 235(8):2303–2314.
  • Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S. 2010. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 34(1):76–80.
  • Sanada K, Nakajima S, Kurokawa S, Barceló-Soler A, Ikuse D, Hirata A, Yoshizawa A, Tomizawa Y, Salas-Valero M, Noda Y, et al. 2020. Gut microbiota and major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 266:1–13.
  • Sarris J. 2016. Kava in the treatment of anxiety. In: Gerbarg P, Brown R, Muskin P, ediors. Complementary and integrative treatments in psychiatric practice. New York: American Psychiatric Publishing.
  • Sarris J, O’Neil A, Coulson CE, Schweitzer I, Berk M. 2014. Lifestyle medicine for depression. BMC Psychiatry. 14(14):107.
  • Sarris J, Ng CH, Schweitzer I. 2012. ‘Omic’ genetic technologies for herbal medicines in psychiatry. Phytother Res. 26(4):522–527.
  • Sarris J, Mischoulon D, Schweitzer I. 2011. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 73(1):81–86.
  • Sarris J, LaPorte E, Schweitzer I. 2011. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 45(1):27–35.
  • Sarris J, Byrne GJ, Bousman CA, Cribb L, Savage KM, Holmes O, Murphy J, Macdonald P, Short A, Nazareth S, et al. 2020. Kava for generalised anxiety disorder: a 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry. 54(3):288–297.
  • Sarris J, Byrne GJ, Bousman C, Stough C, Murphy J, MacDonald P, Adams L, Nazareth S, Oliver G, Cribb L, et al. 2018. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: an 8-week double-blind, randomized, controlled trial. Eur Neuropsychopharmacol. 28(10):1126–1136.
  • Sarris J, Murphy J, Stough C, Mischoulon D, Bousman C, MacDonald P, Adams L, Nazareth S, Oliver G, Cribb L, et al. 2020. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology (Berl). 237(1):209–218.
  • Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. 2016. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 173(6):575–587.
  • Sarris J, Freeman MP. 2020. Omega-3 fatty acid supplementation for perinatal depression and other subpopulations? J Clin Psychiatry. 81(5):20com13489.
  • Sarris J, Marx W, Ashton M, Ng C, Galvao-Coelho N, Ayati Z, Zhang Z, Kasper S, Ravindran A, Harvey B, et al. 2020. Plant-based medicines (phytoceuticals) in the treatment of psychiatric disorders: a meta-review of meta-analyses of randomized controlled trials. Can J Psychiat. 66(10):849–862.
  • Schefft C, Kilarski LL, Bschor T, Köhler S. 2017. Efficacy of adding nutritional supplements in unipolar depression: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 27(11):1090–1109.
  • Shakeri J, Khanegi M, Golshani S, Farnia V, Tatari F, Alikhani M, Nooripour R, Ghezelbash MS. 2016. Effects of omega-3 supplement in the treatment of patients with bipolar I disorder. Int J Prev Med. 7(1):77.
  • Shakibaei F, Radmanesh M, Salari E, Mahaki B. 2015. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. " Complement Ther Clin Pract. 21(2):61–67.
  • Sharef AA-R, Hussien SS, Noori FM. 2020. Vitamin D3 deficiency and early pregnancy loss. ME-JFM. 18 (1):76–80.
  • Shaw K, Turner J, Del Mar C. 2002. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry. 36(4):488–491.
  • Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. 2007. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 7(1):10.
  • Sheikhmoonesi F, Zarghami M, Mamashli S, Charati JY, Hamzehpour R, Fattahi S, Azadbakht R, Kashi Z, Ala S, Moshayedi M. 2016. Effectiveness of vitamin D supplement therapy in chronic stable schizophrenic male patients: a randomized controlled trial. Iran J Pharm Res IJPR. 15(4):941.
  • Srirama R, Santhosh Kumar JU, Seethapathy GS, Newmaster SG, Ragupathy S, Ganeshaiah KN, Uma Shaanker R, Ravikanth G. 2017. Species adulteration in the herbal trade: causes, consequences and mitigation. Drug Saf. 40(8):651–661.
  • Khyati S, Anup T. 2013. A randomized double blind placebo controlled study of ashwagandha on generalized anxiety disorder. Int Ayurvedic Med J. 1:1–7.
  • Szegedi A, Kohnen R, Dienel A, Kieser M. 2005. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 330(7490):503.
  • Teschke R, Sarris J, Glass X, Schulze J. 2011. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol. 71(3):445–448.
  • Trebatická J, Hradečná Z, Surovcová A, Katrenčíková B, Gushina I, Waczulíková I, Sušienková K, Garaiova I, Šuba J, Ďuračková Z. 2020. Omega-3 fatty-acids modulate symptoms of depressive disorder, serum levels of omega-3 fatty acids and omega-6/omega-3 ratio in children. A randomized, double-blind and controlled trial. Psychiatry Res. 287:112911.
  • Turner EH, Loftis JM, Blackwell AD. 2006. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 109(3):325–338.
  • Vellekkatt F, Menon V, Rajappa M, Sahoo J. 2020. Effect of adjunctive single dose parenteral Vitamin D supplementation in major depressive disorder with concurrent vitamin D deficiency: a double-blind randomized placebo-controlled trial . J Psychiatr Res. 129:250–256.
  • Von Kanel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, Hättenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E. 2021. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: a meta-analysis. Brain Behav. 11:e01997.
  • WHO 2020. https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_12020.
  • Wozniak J, Faraone SV, Chan J, Tarko L, Hernandez M, Davis J, Woodworth KY, Biederman J. 2015. A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study. J Clin Psychiatry. 76(11):1548–1555.
  • Xue CC, Zhang AL, Lin V, Da Costa C, Story DF. 2007. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med. 13(6):643–650.
  • Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, Castle DJ, Tan EJ, Phillipou A, Harris AW, et al. 2020. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust NZ J Psychiatry. 54(5):453–466.
  • Zamora J, Velásquez A, Troncoso L, Barra P, Guajardo K, Castillo-Duran C. 2011. Zinc in the therapy of the attention-deficit/hyperactivity disorder in children. A preliminar randomized controlled trial. Arch Latinoam Nutr. 61(3):242–246.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.